Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Reggio Emilia – page 18

246 clinical trials in Reggio Emilia, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Reggio Emilia at a glance
246
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

246 trials in Reggio Emilia

Open in trial search

Bronchiectasis

Not recruiting

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Study of Ibrutinib and Rituximab for Patients with Untreated Marginal Zone Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Neuroendocrine tumour+1

Not recruiting

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Octreotide
  • Sponsor:Advanced Accelerator Applications
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ganciclovir Sodium
  • Sponsor:Viracta Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Reggio Emilia

What the registry says about research in the country

01 Oncology - Solid Tumors

Innovative clinical trials focusing on metastatic colorectal cancer, non-small cell lung cancer, and gastric cancer. Research evaluates novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Colorectal Cancer Treatments
  • Lung Cancer Therapies
  • Gastrointestinal Oncology

Studies include assessment of treatment efficacy and novel drug combinations for advanced stage cancers.

02 Hematologic Malignancies

Groundbreaking research in B-cell lymphomas and chronic myeloid leukemia. Studies evaluate innovative treatment approaches including targeted therapies and combination protocols.

  • Lymphoma Treatments
  • Leukemia Therapies
  • Novel Drug Combinations

Focus on improving patient outcomes through personalized treatment approaches.

03 Autoimmune Conditions

Clinical trials investigating treatments for Sjögren's Syndrome and other inflammatory conditions. Research aims to evaluate long-term safety and efficacy of novel therapeutic agents.

  • Inflammatory Disorders
  • Autoimmune Diseases
  • Novel Therapeutics

Studies focus on developing safer and more effective treatment options for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.